CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
GlobeNewswire
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma..
